Cardiovascular Disease Early Detection and Prevention Act of 2026 mandates coverage of lipoprotein(a) and apolipoprotein B tests without cost sharing.
The Cardiovascular Disease Early Detection and Prevention Act of 2026 aims to improve cardiovascular health by requiring coverage of specific tests without cost sharing. It mandates that group health plans, individual health insurance, Medicare, and Medicaid cover lipoprotein(a) and apolipoprotein B tests for individuals with a family history of premature cardiovascular disease, a personal history of myocardial infarction, stroke, or elevated LDL cholesterol, a diagnosis of diabetes mellitus or obesity, or other recognized cardiovascular risk factors.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.